CJC-1295 with DAC vs Dutasteride
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both CJC-1295 with DAC and Dutasteride can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 with DAC Dutasteride
Weight 3,647.28 Da 528.53 Da
Half-life 6-8 days ~5 weeks (extremely long; active metabolite accumulation over months)
Chain 30 amino acids —
Type GHRH analog with DAC Synthetic 4-azasteroid compound (dual 5-alpha reductase inhibitor)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dutasteride
01 Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
02 Reduces serum DHT by approximately 90%, compared to 70% with finasteride
03 Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
04 FDA-approved for BPH with well-established long-term safety data
05 Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
06 Convenient once-daily oral dosing with no injections required
07 Can be combined with minoxidil for enhanced hair loss treatment
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Dutasteride
0.5mg/day / Once daily or 3x per week
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Dutasteride
Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression)
Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride)
Decreased ejaculate volume (reported in 1-2%)
Gynecomastia or breast tenderness (reported in approximately 1-2%)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Women who are pregnant or may become pregnant (dutasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling damaged capsules poses a risk due to skin absorption)
Women who are breastfeeding
Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component of the formulation
Severe hepatic impairment (dutasteride is extensively metabolized by the liver via CYP3A4)
Pediatric patients (not indicated for use in children)
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may significantly increase dutasteride levels
Research Evidence
CJC-1295 with DAC Dutasteride
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 —
FDA Approved No Yes
Full CJC-1295 with DAC profile Full Dutasteride profile CJC-1295 with DAC calculator Dutasteride calculator
More comparisons: Minoxidil
This comparison is for educational and research purposes only. Consult a healthcare professional before use.